Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reformulated PG324 in Open-Angle Glaucoma or Ocular Hypertension
NCT07082816Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of netarsudil + latanoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Alcon Inc.. Started Sep 2025; status: completed.
02
Drugs
netarsudil + latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT07082816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082816.